2
项与 Autologous Mesenchymal Cells(Bioinova, s.r.o.) 相关的临床试验Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease to Assess the Safety and the Efficacy
Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the subjects were followed up as out-patients during 5 study visits for 12 months in total.
A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on symptoms relief. Over the past few years, stem cell research has expanded greatly as a tool for developing new therapies to treat incurable diseases. Stem cell therapy has been shown as promising in several animal ALS models and human clinical trials.
100 项与 Autologous Mesenchymal Cells(Bioinova, s.r.o.) 相关的临床结果
100 项与 Autologous Mesenchymal Cells(Bioinova, s.r.o.) 相关的转化医学
100 项与 Autologous Mesenchymal Cells(Bioinova, s.r.o.) 相关的专利（医药）
100 项与 Autologous Mesenchymal Cells(Bioinova, s.r.o.) 相关的药物交易
